Hospital Staffing and Patient Outcomes After Private Equity Acquisition
Abstract
BACKGROUND
After private equity acquisition, hospitals may experience changes in staffing with implications for patients.
OBJECTIVE
To examine hospital staffing and patient outcomes in emergency departments (EDs) and intensive care units (ICUs) before and after hospitals were acquired by private equity.
DESIGN
Matched difference-in-differences analysis.
SETTING
100% Medicare Part A and B claims and Cost Report data from 2009 to 2019.
PATIENTS
1 007 529 ED visits and 121 080 ICU hospitalizations across 49 private equity hospitals were compared with 6 179 854 ED visits and 760 377 ICU hospitalizations across 293 matched control hospitals.
MEASUREMENTS
Hospital ED and ICU salary expenditures, patient mortality, length of stay, and transfers. Secondary outcomes included hospital-wide salary expenditures and full-time employees.
RESULTS
After acquisition, private equity hospitals reduced ED salary expenditures by 18.2% (-$12.63 per inpatient bed day; 95% CI, -$22.74 to -$2.52; P = 0.015) and ICU salary expenditures by 15.9% (-$8.46 per inpatient bed day, CI, -$13.21 to -$3.72; P < 0.001) relative to control. This occurred alongside average hospital-wide reductions in full-time employees by 11.6% and salary expenditures by 16.6%, relative to control. Beneficiaries in EDs of private equity hospitals experienced 7.0 additional deaths per 10 000 visits after acquisition relative to control (13.4% increase from a raw baseline of 52.4 deaths per 10 000; P = 0.009). No differential…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.